DAFTAR PUSTAKA

ADA. (2019). Standar Perawatan Medis Pada Diabetes . USA. *American Diabetes Association. Standar Perawatan Medis Pada Diabetes . USA*, *ISSN 0149-*.

Akahani, S., Nangia-Makker, P., Inohara, H., Kim, H.-R. C., & Raz, A. (1997). Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. *Cancer Research*, *57*(23), 5272–5276.

Aravinda, J. (2019). Risk factors in patients with type 2 diabetes in Bengaluru: A retrospective study. *World Journal of Diabetes*, *10*(4), 241.

Arsono, S. (2005). Diabetes melitus sebagai faktor risiko kejadian gagal ginjal terminal (studi kasus pada pasien RSUD Prof. Dr. Margono Soekarjo Purwokerto). *Jurnal Epidemiologi*.

Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020). Type 2 diabetes mellitus: A review of multi-target drugs. In Molecules (Vol. 25, Issue 8). MDPI AG.

Atalar, M. N., Abuşoğlu, S., Ünlü, A., Tok, O., İpekçi, S. H., Baldane, S., & Kebapcılar, L. (2019). Assessment of serum galectin-3, methylated arginine and Hs-CRP levels in type 2 diabetes and prediabetes. *Life Sciences*, *231*, 116577.

Aynalem, S. B., & Zeleke, A. J. (2018). Prevalence of diabetes mellitus and its risk factors among individuals aged 15 years and above in Mizan-Aman town, Southwest Ethiopia, 2016: a cross sectional study. *International Journal of Endocrinology*, *2018*.

Balan, V., Nangia-Makker, P., Schwartz, A. G., Jung, Y. S., Tait, L., Hogan, V., Raz, T., Wang, Y., Yang, Z. Q., & Wu, G. S. (2008). Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. *Cancer Research*, *68*(24), 10045–10050.

Barondes, S. H., Castronovo, V., Cooper, D. N., Cummings, R. D., Drickamer, K., Feizi, T., Gitt, M. A., Hirabayashi, J., Hughes, C., & Kasai, K. (1994). Galectins: a family of animal beta-galactoside-binding lectins. *Cell*, *76*(4).

Chandalia, H. B., & Krishnaswamy, P. R. (2002). Glycated hemoglobin. *Current Science*, 1522–1532.

Clementy, N., Piver, E., Bisson, A., Andre, C., Bernard, A., Pierre, B., Fauchier, L., & Babuty, D. (2018). Galectin-3 in atrial fibrillation: mechanisms and therapeutic implications. *International Journal of Molecular Sciences*, *19*(4), 976.

Damayanti, S. (2015). Diabetes mellitus dan penatalaksanaan keperawatan. *Yogyakarta: Nuha Medika*.

De Boer, R. A., Edelmann, F., Cohen-Solal, A., Mamas, M. A., Maisel, A., & Pieske, B. (2013). Galectin-3 in heart failure with preserved ejection fraction. *European Journal of Heart Failure*, *15*(10), 1095–1101.

De Paoli, M., Zakharia, A., & Werstuck, G. H. (2021). The role of estrogen in insulin resistance: A review of clinical and preclinical data. The American Journal of Pathology, 191(9), 1490-1498

Decroli, E. (2019). Diabetes melitus tipe 2. *Padang: Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas*, 1–52.

Díaz-Alvarez, L., & Ortega, E. (2017). The many roles of galectin-3, a multifaceted molecule, in innate immune responses against pathogens. *Mediators of Inflammation*, *2017*.

Donelly, R., & Bilous, R. (2014). Buku Pegangan Diabetes Edisi Ke-4. *Yogyakarta: Bumi Medika*.

Dong, R., Zhang, M., Hu, Q., Zheng, S., Soh, A., Zheng, Y., & Yuan, H. (2018). Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy. *International Journal of Molecular Medicine*, *41*(2), 599–614.

Dumic, J., Dabelic, S., & Flögel, M. (2006). Galectin-3: an open-ended story. *Biochimica et Biophysica Acta (BBA)-General Subjects*, *1760*(4), 616–635.

Faramarz, I. B. (2012). *Pathogenesis and gtycemic management of type 2 diabetes mellitus: a physiological approach*.

Funasaka, T., Balan, V., Raz, A., & Wong, R. W. (2013). Nucleoporin Nup98 mediates galectin-3 nuclear-cytoplasmic trafficking. *Biochemical and Biophysical Research Communications*, *434*(1), 155–161.

Gupta, S., Jain, U., & Chauhan, N. (2017). Laboratory diagnosis of HbA1c: a review. *J Nanomed Res*, *5*(4), 120.

Gullestad, L., Ueland, T., Kjekshus, J., Nymo, S. H., Hulthe, J.,

Muntendam, P., ... & Aukrust, P. (2012). Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). *European heart journal*, *33*(18), 2290-2296.

Harreiter, J., & Roden, M. (2019). Diabetes mellitus—Definition, classification, diagnosis, screening and prevention (Update 2019). *Wiener Klinische Wochenschrift*, *131*(Update), 6–15. https://doi.org/10.1007/s00508-019-1450-4

Hikmat, P. (2017). Komplikasi Kronik dan Penyakit Penyerita pada Diabetes. *Medical Care*, 1–5. http://pustaka.unpad.ac.id/wp-content/uploads/2009/09/kompilasi_kronik_dan_penyakit_penyerta_pada_diabetesi.pdf

Hughes, R. C. (1994). Mac-2: a versatile galactose-binding protein of mammalian tissues. *Glycobiology*, *4*(1), 5–12.

Iacobini, C., Amadio, L., Oddi, G., Ricci, C., Barsotti, P., Missori, S., Sorcini, M., Di Mario, U., Pricci, F., & Pugliese, G. (2003). Role of galectin-3 in diabetic nephropathy. *Journal of the American Society of Nephrology*, *14*(suppl 3), S264–S270.

Jayaningrum, F. (2016). Aktivitas Media Smart Book dalam Meningkatkan Pengetahuan Tentang Penatalaksanaan Diabetes Mellitus pada Pasien Diabetes Mellitus di Puskesmas Kedungmundu Kota Semarang. *Journal of Health Education*, *1*(2), 9.

Jin, Q., Lou, Y., Li, T., Chen, H., Liu, Q., & He, X. (2013). Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus. *Chinese Medical Journal*, *126*(11), 2109–2115.

Johannes, L., Jacob, R., & Leffler, H. (2018). Galectins at a glance. *Journal of Cell Science*, *131*(9), 1–9. https://doi.org/10.1242/jcs.208884

Kim, H.-R. C., Lin, H.-M., Biliran, H., & Raz, A. (1999). Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. *Cancer Research*, *59*(16), 4148–4154.

Kirwan, J. P., Sacks, J., & Nieuwoudt, S. (2017). The essential role of exercise in the management of type 2 diabetes. *Cleveland Clinic Journal of Medicine*, *84*(7 Suppl 1), S15.

Kleinaki, Z., Kapnisi, S., Theodorelou-Charitou, S.-A., Nikas, I. P., & Paschou, S. A. (2020). Type 2 diabetes mellitus management in patients with chronic kidney disease: an update. *Hormones*, *19*(4), 467–476.

Kusdiyah, E., Makmur, M. J., & Aras, R. B. P. (2020). Karakteristik faktor-faktor risiko terjadinya komplikasi kronik nefropati diabetik dan atau penyakit pembuluh darah perifer pada penderita diabetes mellitus di RSUD Raden Mattaher tahun 2018. *Electronic Journal Scientific of Environmental Health And Disease*, *1*(1).

Leiva, A. M., Martínez, M. A., Petermann, F., Garrido-Méndez, A., Poblete-Valderrama, F., Díaz-Martínez, X., & Celis-Morales, C. (2018). Risk factors associated with type 2 diabetes in Chile. *Nutricion Hospitalaria*, *35*(2), 400–407. https://doi.org/10.20960/nh.1434

LeMone, P., Burke, K. M., & Bauldaff, G. (2015). *Buku ajar keperawatan medikal bedah*.

Li, P., Liu, S., Lu, M., Bandyopadhyay, G., Oh, D., Imamura, T., Johnson, A. M. F., Sears, D., Shen, Z., & Cui, B. (2016). Hematopoietic-derived galectin-3 causes cellular and systemic insulin resistance. *Cell*, *167*(4), 973–984.

Li, S., Guo, S., He, F., Zhang, M., He, J., Yan, Y., Ding, Y., Zhang, J., Liu, J., & Guo, H. (2015). Prevalence of diabetes mellitus and impaired fasting glucose, associated with risk factors in rural Kazakh adults in Xinjiang, China. *International Journal of Environmental Research and Public Health*, *12*(1), 554–565.

Li, Y.-S., Li, X.-T., Yu, L.-G., Wang, L., Shi, Z.-Y., & Guo, X.-L. (2020). Roles of galectin-3 in metabolic disorders and tumor cell metabolism. *International Journal of Biological Macromolecules*, *142*, 463–473.

Li, Y., Li, T., Zhou, Z., & Xiao, Y. (2022). Emerging roles of Galectin-3 in diabetes and diabetes complications: A snapshot. *Reviews in Endocrine and Metabolic Disorders*, *23*(3), 569–577. https://doi.org/10.1007/s11154-021-09704-7

Liana, P., & Suryaatmadja, M. (2013). *Small dense LDL as risk factor of cardiovascular disease in prediabetes of first degree relative from patients with type 2 diabetes mellitus*. Pactoconvex Niagatama.

Lin, D., Hong, X., Sun, K., Zhang, X., Lian, H., Wang, J., Mao, N., Zhang, X., Ren, M., & Yan, L. (2021). Galectin-3/adiponectin as a new biological indicator for assessing the risk of type 2 diabetes: a cross-sectional study in a community population. *Aging (Albany NY)*, *13*(11), 15433.

Lok, D. J. A., Van Der Meer, P., de la Porte, P. W., Lipsic, E., Van Wijngaarden, J., Hillege, H. L., & van Veldhuisen, D. J. (2010). Prognostic value of galectin-3, a novel marker of fibrosis, in patients

with chronic heart failure: data from the DEAL-HF study. *Clinical Research in Cardiology*, *99*(5), 323–328.

Ma, S., Li, S., Lv, R., Hou, X., Nie, S., & Yin, Q. (2020). Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin-3 level. *Journal of Diabetes Investigation*, *11*(5), 1295–1302. https://doi.org/10.1111/jdi.13256

Marbun, K. (2018). *Pemeriksaan Kadar HbA1c Pada Penderita Diabetes Melitus Tipe II Yang di Rawat Jalan Di RSUP H. Adam Malik Medan*.

Monteiro, R., Teixeira, D., & Calhau, C. (2014). Estrogen signaling in metabolic inflammation. Mediators of inflammation, 2014.

Nabila. (2018). *Hubungan Kadar HbA1C terhadap Kadar GDP Pada Penderita DM Tipe 2 di RSUP Haji Adam Malik*. Universitas Sumatera Utara.

Owora, A. H. (2018). Diagnostic validity and clinical utility of HbA1c tests for type 2 diabetes mellitus. *Current Diabetes Reviews*, *14*(2), 196.

Ozturk, D., Celik, O., Satilmis, S., Aslan, S., Erturk, M., Cakmak, H. A., Kalkan, A. K., Ozyilmaz, S., Diker, V., & Gul, M. (2015). Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. *Coronary Artery Disease*, *26*(5), 396–401.

PERKENI. (2021). *Buku Pedoman Pengelolaan dan Pencegahan Diabetes Melitus tipe 2 dewasa di Indonesia.*

Petrovic, I., Pejnovic, N., Ljujic, B., Pavlovic, S., Miletic Kovacevic, M., Jeftic, I., Djukic, A., Draginic, N., Andjic, M., & Arsenijevic, N. (2020). Overexpression of galectin 3 in pancreatic β cells amplifies β-cell apoptosis and islet inflammation in type-2 diabetes in mice. *Frontiers in Endocrinology*, *11*, 30.

Powers, A. (2005). No Title. *Diabetes Mellitus in Harrison's Principles of Internal Medicine*, *2 MCGraw-H*(2152-63.).

Pranoto, A. (2019). Kendali Glikemik pada Pasien Diabetes Melitus Tipe 2 dengan dan tanpa Tuberkulosis Paru. *Jurnal Media Kesehatan Masyarakat Indonesia*, *15*(1), 99–109.

Pugliese, G., Iacobini, C., Ricci, C., Fantauzzi, C. B., & Menini, S. (2014). Galectin-3 in diabetic patients. *Clinical Chemistry and Laboratory Medicine (CCLM)*, *52*(10), 1413–1423.

Punthakee, Z., Goldenberg, R., & Katz, P. (2018). Definition, classification

and diagnosis of diabetes, prediabetes and metabolic syndrome. *Canadian Journal of Diabetes*, *42*, S10–S15.

Que, A., Yasa, I. W. P. S., & Lestari, A. A. W. (2015). Gambaran Hasil Pemeriksaan Kadar Hba1c Pada Penderita Diabetes Mellitus di Laboratorium Rumah Sakit Umum Surya Husadha Tahun 2013. In *E-Jurnal Medika Udayana* (pp. 1395–2303). dec.

RI, P. K. (2018). *Lindungi Keluarga Dari Diabetes*. Kementerian Kesehatan Republik Indonesia. http://p2ptm. kemkes. go. id/post ….

Richardson, J. W., Kelly, K. D., Kumodzi, T. K., Liburd, N. S., & Laws, H. (2019). Type 2 Diabetes Prevalence, Distribution and Risk Factors in St. Kitts and Nevis, West Indies. *International Journal of Diabetes and Clinical Research*, *6*(4).

Riskesdas. (2018). No Title. *Hasil Utama Riset Kesehatan Dasar. Badan Pengembangan Dan Penelitian Kesehatan*.

Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., Shaw, J. E., Bright, D., & Williams, R. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Research and Clinical Practice*, *157*, 107843. https://doi.org/10.1016/j.diabres.2019.107843

Samanta, S. (2020). Glycated hemoglobin and subsequent risk of microvascular and macrovascular complications. *Indian Journal of Medical Sciences*, *73*(2), 230–238. https://doi.org/10.25259/ijms_16_2020

Sambara, Y. (2013). Patomekanisme Kerusakan Ginjal Pada Penderita Diabetes Mellitus Tipe 2. Universitas Hasanuddin.

Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin III, J. R., & Aguilar, R. B. (2016). The time is right for a new classification system for diabetes: rationale and implications of the β-cell–centric classification schema. *Diabetes Care*, *39*(2), 179–186.

Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G. P., Bellotti, C., Salehi, L. B., & Ricci, A. (2018). Galectin-3: one molecule for an alphabet of diseases, from A to Z. *International Journal of Molecular Sciences*, *19*(2), 379.

Sharma, J. R., Agraval, H., & Yadav, U. C. S. (2023). Cigarette smoke induces epithelial-to-mesenchymal transition, stemness, and

metastasis in lung adenocarcinoma cells via upregulated RUNX-2/galectin-3 pathway. *Life Sciences*, *318*, 121480.

Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., & Sakharkar, M. K. (2016). Significance of HbA1c test in diagnosis and prognosis of diabetic patients. *Biomarker Insights*, *11*, BMI-S38440.

Sirenko, O., & Kuryata, O. (2022). ANDROGEN Deficiency Associates With Increased Advanced Glycated End Products, Galectin-3 in Hypertensive Men With Benign Prostatic Hyperlapsia. *Journal of Hypertension*, *40*(Suppl 1), e158-e158.

Speeckaert, M., Van Biesen, W., Delanghe, J., Slingerland, R., Wiecek, A., Heaf, J., Drechsler, C., Lacatus, R., Vanholder, R., & Nistor, I. (2014). Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? *Nephrology Dialysis Transplantation*, *29*(12), 2167–2177.

Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995). Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. *New England Journal of Medicine*, *333*(9), 550–554.

Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., Pavkov, M. E., Ramachandaran, A., Wild, S. H., James, S., Herman, W. H., Zhang, P., Bommer, C., Kuo, S., Boyko, E. J., & Magliano, D. J. (2022). IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Research and Clinical Practice*, *183*, 109119. https://doi.org/10.1016/j.diabres.2021.109119

Suthahar, N., Meijers, W. C., Silljé, H. H. W., Ho, J. E., Liu, F.-T., & de Boer, R. A. (2018). Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update. *Theranostics*, *8*(3), 593.

Suyono, S. (2006). Diabetes melitus di Indonesia. *Buku Ajar Ilmu Penyakit Dalam*.

Tiwari, A.K.,dkk., 2002.Diabetes melitus dan Terapi : kondisi saat ini dan masa depan. vol 83, 1 (30-38).

Trimboli, P., Virili, C., Romanelli, F., Crescenzi, A., & Giovanella, L. (2017). Galectin-3 performance in histologic and cytologic assessment of thyroid nodules: A systematic review and Meta-analysis. *International Journal of Molecular Sciences*, *18*(8), 1756.

Usha, S., Suman, S., & Shailja, S. (2011). Plasma endothelin level in hypertension and diabetes mellitus. *Medical Case Studies*, *2*(6), 50–

53.

Utomo, A. A., Rahmah, S., & Amalia, R. (2020). Faktor Risiko Diabetes Mellitus Tipe 2: A Systematic Review. *AN-NUR: Jurnal Kajian Dan Pengembangan Kesehatan Masyarakat*, *1*(1), 44–53.

Vijayakumar, S., Peng, H., & Schwartz, G. J. (2013). Galectin-3 mediates oligomerization of secreted hensin using its carbohydrate-recognition domain. *American Journal of Physiology-Renal Physiology*, *305*(1), F90–F99.

Vora, A., De Lemos, J. A., Ayers, C., Grodin, J. L., & Lingvay, I. (2019). Association of galectin-3 with diabetes mellitus in the dallas heart study. *The Journal of Clinical Endocrinology & Metabolism*, *104*(10), 4449–4458.

Wan, L., & Liu, F.-T. (2016). Galectin-3 and Inflammation. *Glycobiology Insights*, *6*.

Wang, J., Luo, X., Jin, X., Lv, M., Li, X., Dou, J., Zeng, J., An, P., Chen, Y., Chen, K., & Mu, Y. (2020). Effects of Preoperative HbA1c Levels on the Postoperative Outcomes of Coronary Artery Disease Surgical Treatment in Patients with Diabetes Mellitus and Nondiabetic Patients: A Systematic Review and Meta-Analysis. *Journal of Diabetes Research*, *2020*, 1–14. https://doi.org/10.1155/2020/3547491

Weber, F., Shen, L., Aldred, M. A., Morrison, C. D., Frilling, A., Saji, M., Schuppert, F., Broelsch, C. E., Ringel, M. D., & Eng, C. (2005). Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. *The Journal of Clinical Endocrinology & Metabolism*, *90*(5), 2512–2521.

Weigert, J., Neumeier, M., Wanninger, J., Bauer, S., Farkas, S., Scherer, M. N., Schnitzbauer, A., Schäffler, A., Aslanidis, C., & Schölmerich, J. (2010). Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. *The Journal of Clinical Endocrinology & Metabolism*, *95*(3), 1404–1411.

WHO. (2022). *DIABETES*. https://www.who.int/health-topics/diabetes#tab=tab_1.

Wibisono, C., Fajar, A., Tjokroprawiro, A., Soetjahjo, A., Pranoto, A., Adi, S., & Murtiwi, S. (2012). Profil albuminuria dan kadar sVCAM-1 pada penderita diabetes melitus tipe 2. *Jurnal Penyakit Dalam*, *13*, 28–35.

Yang, R.-Y., Hsu, D. K., & LIu, F.-T. (1996). Expression of galectin-3

modulates T-cell growth and apoptosis. *Proceedings of the National Academy of Sciences*, *93*(13), 6737–6742.

Yang, R.-Y., Rabinovich, G. A., & Liu, F.-T. (2008). Galectins: structure, function and therapeutic potential. *Expert Reviews in Molecular Medicine*, *10*.

Yunanto, K. W. (2018). *pengetahuan, sikap dan tindakan terhadap pola hidup terkait faktor risiko diabetes melitus tipe 2 pada remaja di Kecamatan Kraton Yogyakarta. jurnal keperawatan, 1*.

Yilmaz, H., Celik, H. T., Ozdemir, O., Kalkan, D., Namuslu, M., Abusoglu, S., ... & Yigitoglu, R. (2014). Serum galectin-3 levels in women with PCOS. *Journal of endocrinological investigation*, *37*, 181-187.

Zheng, Y., Ley, S. H., & Hu, F. B. (2018). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nature Reviews Endocrinology*, *14*(2), 88–98. https://doi.org/10.1038/nrendo.2017.151

Zulfahmidah, Fajriansyah, Armanto Makmun, Rasfahyana, 2021. Hubungan obesitas dan stres oksidatif. UMI Medical Journal Vol.6

LAMPIRAN

LAMPIRAN

Lampiran 1. Surat Izin Etik

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person dr. Agussalim Bukhari ,MMed,PhD, SpGK TELP. 085241930858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK
Nomor : 85/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 2 Februari 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23010006	No Sponsor Protokol	
Peneliti Utama	**Zaifah Firayanti**	Sponsor	
Judul Peneliti	Analisis Hubungan HbA1c dengan Kadar Galectin-3 Serum Pada Subjek Diabetes Melitus Tipe 2		
No Versi Protokol	2	Tanggal Versi	**31 Januari 2023**
No Versi PSP	2	Tanggal Versi	**31 Januari 2023**
Tempat Penelitian	RS Universitas Hasanuddin Makassar		
Jenis Review	[ ] Exempted [x] Expedited [ ] Fullboard Tanggal	Masa Berlaku **2 Februari 2023** sampai **2 Februari 2024**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:
- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. Surat Izin Penelitian

HUM-RC	ADMINISTRASI	FORMULIR 1
	Nomor : 047/02/FR1/2023	Tanggal : 6 Februari 2023
SURAT PENGANTAR PENELITIAN		

Kepada Yth.

Pembimbing/pendamping,

Bpk. Muh. Yusuf Usman,

Dengan ini menerangkan bahwa peneliti/mahasiswa berikut ini :

Nama	: Zalfah Firayanti
NIM	: P062212006
Institusi	: Pascasarjana Ilmu Biomedik Universitas Hasanuddin

Akan melakukan pengambilan data/ analisa bahan hayati :

Pada tanggal	: 9 Februari 2023 s/d Selesai
Jumlah subjek	: ± 62 sampel
Jenis data	: Data Primer

Untuk penelitian dengan judul :

"Analisis Hubungan Hba1c dengan Kadar Galectin-3 Serum Pada Subjek Diabetes Melitus Tipe 2"

Harap dilakukan pembimbingan dan pendampingan seperlunya. Terima Kasih.

Staf Administrasi,

HUM-RC science for a better future

Andi Fidyah Septiani

Catatan :

Jika pengambilan data telah selesai, **di wajibkan bagi pendamping/pembimbing:**

1. Membubuhi **paraf dan tanggal selesai** pengembilan data di formulir ini,
2. Mengisi **jumlah alat dan bahan habis pakai** yang digunakan peneliti pada form tarif penggunaan alat dan bahan,
3. **Mengembalikan formulir** yang sudah lengkap ke staf administrasi.

Lampiran 3. Data Primer

No Sampel	Jenis Kelamin	Umur	HbA1c	*Galectin-3* Serum
101	P	63	12.4	23.8651
14	P	55	10.3	16.84022
19	L	60	7.6	25.32551
21	P	56	10	24.62647
22	P	61	8.3	28.12915
23	L	53	9.4	1.082064
24	P	64	9	15.36839
26	L	69	8,0	13.86711
27	P	56	8.1	14.44248
32	P	62	11.6	26.0627
33	P	50	11.1	26.73627
34	P	53	11.1	24.85315
37	L	37	10.4	13.94136
39	P	63	8.2	28.57744
40	P	49	7.9	17.60109
42	P	63	10,0	12.27535
43	P	58	10.1	20.64169
44	P	59	7.4	20.13889
45	L	65	7.7	29.00808
46	P	43	11.5	26.28997
47	L	60	8.3	20.089
48	L	63	15.9	24.68217
49	L	62	9.9	7.602462
56	P	61	14.4	17.74597
58	L	70	7.7	24.22335
61	P	63	10.8	25.78848
62	L	54	9,0	18.94239
65	L	56	13.6	8.146832
66	P	39	7,0	22.61465
73	L	79	7.7	24.86824
74	P	48	7.9	26.39665
76	L	61	7.6	20.00946
77	L	61	10.6	12.57619
78	P	73	7.2	23.50415
80	P	53	8.8	26.50536
81	P	52	7	23.85727
82	L	67	9.7	22.54081

84	L	61	10.1	15.288
86	L	47	9.7	24.61234
87	P	64	11.5	25.88335
88	P	46	9.6	18.09633
89	L	84	9.2	15.60424
90	P	65	13.8	18.92908
94	L	57	7.1	20.84981
95	P	63	9.4	17.62608
96	L	53	7.2	8.849652
97	P	58	7.2	23.98977
99	L	39	8.5	21.25984
105	P	58	13.9	18.29926
25	L	68	6.6	8.654182
50	P	56	6.3	22.07413
54	L	44	6.6	0.18263
71	L	63	6.2	12.54362
79	L	42	6.5	23.22995
91	P	67	6.9	18.12318
92	L	61	6.7	18.44517
93	P	72	6,0	14.46535
98	L	52	5.9	16.54308
103	L	62	6.5	13.29142
104	P	56	5.7	15.25746

Lampiran 4. Analisis Data

Statistik Deskriptif

Jenis Kelamin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki	28	46.7	46.7	46.7
	Perempuan	32	53.3	53.3	100.0
	Total	60	100.0	100.0	

Usia

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	36-45 tahun	6	10.0	10.0	10.0
	46-55 tahun	13	21.7	21.7	31.7
	56-65 tahun	32	53.3	53.3	85.0
	>65 tahun	9	15.0	15.0	100.0
	Total	60	100.0	100.0	

Descriptive Statistics

	N	Range	Minimum	Maximum	Mean	Std. Deviation
HbA1c	60	10.20	5.70	15.90	9.0050	2.32295
Galectin-3	60	28.82540	.18260	29.00800	19.1976772	6.49611139
Valid N (listwise)	60					

Statistics

		Gal-3 Tidak Terkendali (Laki-laki)	Gal-3 Terkendali (Laki-laki)	Gal-3 Tidak Terkendali (Perempuan)	Gal-3 Terkendali (Perempuan)
N	Valid	21	7	28	4
	Missing	0	0	0	0
Mean		17.7794	13.2700	21.9887	17.4800
Median		20.0094	13.2914	23.6807	16.6903
Mode		1.08[a]	.18[a]	12.28[a]	14.47[a]
Std. Deviation		7.23864	7.41405	4.54742	3.44227
Range		27.93	23.05	16.30	7.61
Minimum		1.08	.18	12.28	14.47

Maximum	29.01	23.23	28.58	22.07

a. Multiple modes exist. The smallest value is shown

Uji Normalitas

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
HbA1c	.119	60	.033	.932	60	.002
Galectin-3	.099	60	.200*	.941	60	.006

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Gal-3 Tidak Terkendali (Laki-laki)	.145	21	.200*	.948	21	.319

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Gal-3 Terkendali (Laki-laki)	.175	7	.200*	.971	7	.903

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	df	Sig.
Gal-3 Tidak Terkendali (Perempuan)	.166	28	.046	.932	28	.068

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Gal-3 Terkendali (Perempuan)	.241	4	.	.916	4	.514

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Hba1c (Laki-laki)	.151	28	.103	.856	28	.001
Gal-3 (Laki-laki)	.103	28	.200*	.957	28	.292

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	df	Sig.
Hba1c (Perempuan)	.115	32	.200*	.958	32	.240
Gal-3 (Perempuan)	.142	32	.100	.939	32	.071

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	df	Sig.
Hba1c Tidak Terkendali	.115	49	.117	.910	49	.001
Gal-3 Tidak Terkendali	.134	49	.029	.933	49	.008

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Hba1c Terkendali	.198	11	.200*	.957	11	.738
Gal-3 Terkendali	.180	11	.200*	.929	11	.400

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Uji Perbandingan

Group Statistics

	HbA1c	N	Mean	Std. Deviation	Std. Error Mean
Galectin-3	Terkendali	11	14.8009242	6.40681749	1.93172816
	Tidak terkendali	49	20.1847687	6.15580303	.87940043

Statistics

Terkendali

N	Valid	11
	Missing	0
Mean		14.8009242
Median		15.2574618
Mode		.18263[a]
Std. Deviation		6.40681749
Minimum		.18263
Maximum		23.22995

a. Multiple modes exist. The smallest value is shown

Statistics

Tidak Terkendali

N	Valid	49
	Missing	0
Mean		20.1847687
Median		20.8498095
Mode		1.08206[a]
Std. Deviation		6.15580303
Minimum		1.08206
Maximum		29.00808

a. Multiple modes exist. The smallest value is shown

Group Statistics

	Kelompok	N	Mean	Std. Deviation	Std. Error Mean
Gal-3 (Laki-laki)	Gal-3 Tidak Terkendali (Laki-laki)	21	17.7794	7.23864	1.57960
	Gal-3 Terkendali (Laki-laki)	7	13.2700	7.41405	2.80225

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Gal-3 (Laki-laki)	Equal variances assumed	.175	.679	1.419	26	.168	4.50947	3.17703	-2.02101	11.03996
	Equal variances not assumed			1.402	10.112	.191	4.50947	3.21679	-2.64719	11.66613

Group Statistics

	Kelompok	N	Mean	Std. Deviation	Std. Error Mean
Gal-3 (Perempuan)	Gal-3 Tidak Terkendali (Perempuan)	28	21.9887	4.54742	.85938
	Gal-3 Terkendali (Perempuan)	4	17.4800	3.44227	1.72114

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Gal-3 (Perempuan)	Equal variances assumed	1.636	.211	1.896	30	.068	4.50870	2.37824	-.34831	9.36572
	Equal variances not assumed			2.344	4.650	.070	4.50870	1.92376	-.55047	9.56788

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
Galectin-3	Equal variances assumed	.109	.742	-2.603	58	.012	-5.38384456	2.06851835	-9.52443390	-1.24325522
	Equal variances not assumed			-2.537	14.445	.023	-5.38384456	2.12247940	-9.92298505	-.84470407

Uji Korelasi Spearman

Correlations

			HbA1c	Galectin-3
Spearman's rho	HbA1c	Correlation Coefficient	1.000	.176
		Sig. (2-tailed)	.	.179
		N	60	60
	Galectin-3	Correlation Coefficient	.176	1.000
		Sig. (2-tailed)	.179	.
		N	60	60

Correlations

			Hba1c (Laki-laki)	Gal-3 (Laki-laki)
Spearman's rho	Hba1c (Laki-laki)	Correlation Coefficient	1.000	.014
		Sig. (2-tailed)	.	.945
		N	28	28
	Gal-3 (Laki-laki)	Correlation Coefficient	.014	1.000
		Sig. (2-tailed)	.945	.
		N	28	28

Correlations

			Hba1c Tidak Terkendali	Gal-3 Tidak Terkendali
Spearman's rho	Hba1c Tidak Terkendali	Correlation Coefficient	1.000	-.072
		Sig. (2-tailed)	.	.625
		N	49	49
	Gal-3 Tidak Terkendali	Correlation Coefficient	-.072	1.000
		Sig. (2-tailed)	.625	.
		N	49	49

Correlations

		Hba1c Terkendali	Gal-3 Terkendali
Hba1c Terkendali	Pearson Correlation	1	-.086
	Sig. (2-tailed)		.801
	N	11	11
Gal-3 Terkendali	Pearson Correlation	-.086	1
	Sig. (2-tailed)	.801	
	N	11	11

Grafik Scatterplot Antara HbA1c dan *Galectin-3* Serum



Lampiran 5. Dokumentasi




ELISA READER